CARDIOL THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.45 CAD | -2.00% |
|
-0.81% | +122.73% |
| Apr. 22 | HC Wainwright Starts Cardiol Therapeutics With Buy Rating, $9 Price Target | MT |
| Apr. 01 | Cardiol Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 118.5 | 91.34 | 142 | 43.96 | 71.77 | 167.3 | - | - |
| Enterprise Value (EV) 1 | 111.8 | 77.47 | 142 | 43.96 | 36.84 | 148.5 | 153.7 | 167.3 |
| P/E ratio | -8.64 x | -4.03 x | -3.19 x | -1.41 x | -2.5 x | -6.45 x | -6.45 x | -5.98 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | 1,803 x | - | - | - | - | 30.1 x |
| EV / Revenue | - | - | 1,803 x | - | - | - | - | 30.1 x |
| EV / EBITDA | -10.4 x | -4.38 x | -4.74 x | -1.07 x | -1.25 x | -10.3 x | -6.7 x | -5.62 x |
| EV / FCF | -9.47 x | -8.4 x | -6.03 x | - | -1.46 x | -9.4 x | -8.76 x | -5.49 x |
| FCF Yield | -10.6% | -11.9% | -16.6% | - | -68.5% | -10.6% | -11.4% | -18.2% |
| Price to Book | - | - | - | - | 2.55 x | 8.36 x | 13.9 x | - |
| Nbr of stocks (in thousands) | 25,878 | 32,856 | 60,954 | 63,703 | 65,247 | 68,284 | - | - |
| Reference price 2 | 4.580 | 2.780 | 2.330 | 0.6900 | 1.100 | 2.450 | 2.450 | 2.450 |
| Announcement Date | 3/26/20 | 3/31/21 | 3/23/22 | 3/28/23 | 4/1/24 | - | - | - |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 0.0788 | - | - | - | - | 5.567 |
| EBITDA 1 | -10.71 | -17.7 | -29.95 | -41.12 | -29.54 | -14.4 | -22.93 | -29.74 |
| EBIT 1 | -13.98 | -20.53 | -38.66 | -41.34 | -29.79 | -32.95 | -31.71 | -35.13 |
| Operating Margin | - | - | -49,091.92% | - | - | - | - | -631.16% |
| Earnings before Tax (EBT) 1 | -13.68 | -20.64 | -31.64 | -30.93 | -28.13 | -26.28 | -28.25 | -32.45 |
| Net income 1 | -13.68 | -20.64 | -31.64 | -30.93 | -28.13 | -26.28 | -28.25 | -32.45 |
| Net margin | - | - | -40,170.44% | - | - | - | - | -582.93% |
| EPS 2 | -0.5300 | -0.6900 | -0.7300 | -0.4900 | -0.4400 | -0.3800 | -0.3800 | -0.4100 |
| Free Cash Flow 1 | -11.8 | -9.226 | -23.56 | - | -25.24 | -15.8 | -17.55 | -30.5 |
| FCF margin | - | - | -29,918.36% | - | - | - | - | -547.9% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/26/20 | 3/31/21 | 3/23/22 | 3/28/23 | 4/1/24 | - | - | - |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | -8.453 | - | -9.178 | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | - | -13.1 | -9.788 | -9.232 | -13.22 | -9.095 | -7.786 | -6.315 | -7.656 | -8.029 | -8.25 | -8.3 | -8.4 | -8.05 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -6.257 | -8.954 | -6.489 | -7.972 | -7.515 | -7.089 | -7.472 | -5.93 | -7.637 | -6.9 | -7 | -7.1 | -6.65 |
| Net income 1 | - | -6.257 | -8.954 | -6.489 | -7.972 | -7.515 | -7.089 | -7.472 | -5.93 | -7.637 | -6.9 | -7 | -7.1 | -6.65 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | - | -0.1100 | -0.1400 | -0.1000 | -0.1300 | -0.1100 | -0.1100 | -0.1200 | -0.0900 | -0.1200 | -0.1050 | -0.1050 | -0.1050 | -0.0900 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/15/21 | 3/23/22 | 5/16/22 | 8/10/22 | 11/10/22 | 3/28/23 | 5/15/23 | 8/10/23 | 11/14/23 | 4/1/24 | - | - | - | - |
1CAD in Million2CAD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 6.77 | 13.9 | - | - | 34.9 | 18.8 | 13.6 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -11.8 | -9.23 | -23.6 | - | -25.2 | -15.8 | -17.6 | -30.5 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | - | - | - | 0.4300 | 0.2900 | 0.1800 | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | - | - | 0.01 | - | 0.06 | - | 0.31 | - |
| Capex / Sales | - | - | 16.4% | - | - | - | - | - |
| Announcement Date | 3/26/20 | 3/31/21 | 3/23/22 | 3/28/23 | 4/1/24 | - | - | - |
1CAD in Million2CAD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.45
CAD
Average target price
4.5
CAD
Spread / Average Target
+83.67%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +122.73% | 122M | |
| +1.51% | 42.75B | |
| +47.64% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- CRDL Stock
- Financials Cardiol Therapeutics Inc.
